Atlas Trials

Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK

Clinical trial NCT04546789 · COMPLETED

Trial details

NCT number
NCT04546789
Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2020-09-30
Primary completion
2021-05-16
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.